NZORD Newsletter 2006 #3 -- 11 May 2006
NZORD - the New Zealand Organisation for Rare Disorders
In
this issue:
1 - 2006 Genethics competition for secondary
school students.
2 - Good news for rare disorders in
Medicines Strategy announcement.
3 - NZORD submission on
Direct-to-Consumer Advertising of prescription
medicines.
4 - Amended link for International Genetic
Alliance position statement on rare
diseases.
*********
1 - 2006 Genethics competition for
secondary school students.
For the third year running
NZORD, the Bioethics Council and the Royal Society are
joining forces to bring the Genethics competition to NZ
secondary schools. This year the focus is newborn metabolic
screening. Part of the essay will require students to
explain the science, genetics and decision-making processes
involved in the screening programme, but they will also need
to research and discuss age-old questions associated with
screening of babies with the Guthrie Card test: Babies’best
interests or mothers’ choice? Which should prevail?
The
topic is very timely as there is new technology expanding
the capability of newborn metabolic screening and important
decisions will be made about the screening programme this
year. As we gain greater capacity with such programmes it is
wise to revisit the ethical and consent issues, which are
crucial elements in all screening programmes. Read more at
the Royal Society website for competition criteria and
scenario. The scenario is also in the News and Issues
section of the NZORD website.
2 - Good news for rare
disorders in Medicines Strategy announcement.
The
government’s announcement just before Easter of a timetable
for the development of a Medicines Strategy for New Zealand
is very good news indeed for rare disease patients and their
support groups. This announcement fulfils a promise in the
post-election confidence and supply agreement between United
Future and Labour. We are very pleased to see specific
mention in the announcement of a focus on “access to
new/innovative/high cost medicines (especially those for
niche groups e.g. rare diseases)”. A lot of hard work over
many years has paid off with this specific inclusion in the
review. Consultation on the strategy should be completed in
early 2007 with decisions expected soon after that. Click
here for the press release from the Associate Health
Minister.
The best news is that the process will not focus all its attention on Pharmac. There is much more to the subject of medicine access than simply rationing the pharmaceutical budget, yet that has been the dominant issue for many years now. The new strategy process indicates a refreshingly open approach to a broader range of issues and NZORD will be working closely with the Access to Medicines Coalition to ensure ethical considerations, legal rights, public law obligations, standards of care and professional best practice, are all factored into the mix. We’ll also be urging government to maintain a high-level interest in the setting of standards and strategies for the benefit of society, and resist the temptation for them to be overly influenced by the conflicting interest in keeping expenditure as low as possible.
3 - NZORD submission
on Direct-to-Consumer Advertising of prescription
medicines.
The Ministry of Health’s consultation process
on DTCA closed early this month. This was not such an easy
topic to submit on. It is not clear whether this issue is a
matter of concern for support groups, or what the consensus
view might be, so a number of open-ended observations were
made based on past discussions with various support group
leaders. Click here to read the submission from NZORD.
4 - Amended link for International Genetic Alliance
position statement on rare diseases.
Whoops, it just
happens from time to time. Our last newsletter included an
invalid link to this document. Click here to read the
position statement of the International Genetic Alliance on
rare diseases. NZORD played a key role in the development of
this paper. We hope that support now given by similar
organisations in over 30 countries will improve our chances
of achieving some of these objectives here in New Zealand,
as well as improve opportunities in other countries.
ENDS